

# Ravi Bhatia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/354272/publications.pdf>

Version: 2024-02-01

219  
papers

8,959  
citations

44444

50  
h-index

49824

91  
g-index

222  
all docs

222  
docs citations

222  
times ranked

11498  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, , .	0.7	2
2	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 1991-2003.	0.8	11
3	Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma. <i>Cancer</i> , 2022, 128, 1392-1401.	2.0	3
4	Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
5	Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients. <i>JAMA Oncology</i> , 2022, 8, 1068.	3.4	5
6	Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2022, 117, 106844.	0.4	7
7	A phase 1 study of NTX-301, an oral DNMT1 inhibitor, in patients with MDS and AML (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7077-TPS7077.	0.8	1
8	Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18808-e18808.	0.8	0
9	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. <i>Blood</i> , 2021, 137, 471-484.	0.6	70
10	Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1364-1372.	1.3	4
11	Metabolic alterations mediated by STAT3 promotes drug persistence in CML. <i>Leukemia</i> , 2021, 35, 3371-3382.	3.3	19
12	Methylation of dual-specificity phosphatase 4 controls cell differentiation. <i>Cell Reports</i> , 2021, 36, 109421.	2.9	17
13	TNF-Î±-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling. <i>Cell Reports</i> , 2021, 36, 109386.	2.9	15
14	Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades. <i>JAMA Oncology</i> , 2021, 7, 1626.	3.4	33
15	Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4727-4740.	2.5	12
16	Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2322-2322.	0.6	0
17	Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report. <i>Blood</i> , 2021, 138, 3923-3923.	0.6	0
18	Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report. <i>Blood</i> , 2021, 138, 484-484.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Risk Factors and Outcomes of ICU Admission Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1784-1784.	0.6	0
20	Essential Roles of Transcription Factor MEF2D in the Maintenance of MLL-Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2218-2218.	0.6	0
21	Fattening up FLT3-ITD for the kill. <i>Blood</i> , 2021, 138, 2158-2159.	0.6	0
22	CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia. <i>Cell Reports</i> , 2020, 31, 107684.	2.9	28
23	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. <i>Blood</i> , 2020, 135, 2337-2353.	0.6	49
24	Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors. <i>Vascular Medicine</i> , 2020, 25, 246-254.	0.8	6
25	A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells. <i>Haematologica</i> , 2020, 105, 2095-2104.	1.7	9
26	Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status. <i>JAMA Oncology</i> , 2020, 6, 542.	3.4	8
27	Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. <i>Journal of Biological Chemistry</i> , 2020, 295, 17935-17949.	1.6	8
28	CXCL12 Knock-out Enhances Leukemia Stem Cell Response to Combination Chemotherapy Plus Tyrosine Kinase Inhibition in Flt3-ITD Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.	0.6	13
29	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. <i>Cancer</i> , 2019, 125, 4033-4042.	2.0	3
30	Mapping Distinct Bone Marrow Niche Populations and Their Differentiation Paths. <i>Cell Reports</i> , 2019, 28, 302-311.e5.	2.9	167
31	Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells. <i>Cell Stem Cell</i> , 2019, 24, 769-784.e6.	5.2	141
32	Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. <i>Cancer</i> , 2019, 125, 2570-2578.	2.0	10
33	SIRT1 regulates metabolism and leukemogenic potential in CML stem cells. <i>Journal of Clinical Investigation</i> , 2019, 129, 2685-2701.	3.9	56
34	An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 2524-2524.	0.6	3
35	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE <sup>®</sup> (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 833-833.	0.6	55
36	Pricing of First and Second Generation Tyrosine Kinase Inhibitors (TKIs) Pre- and Post-Transition of Imatinib to Generic Status. <i>Blood</i> , 2019, 134, 2140-2140.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Role of Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment. <i>Blood</i> , 2019, 134, 2548-2548.	0.6	1
38	TARGETING LEUKEMIA STEM CELL RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIA. <i>Transactions of the American Clinical and Climatological Association</i> , 2019, 130, 246-254.	0.9	6
39	hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. <i>Blood</i> , 2018, 131, 1532-1544.	0.6	40
40	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. <i>Nature Medicine</i> , 2018, 24, 450-462.	15.2	123
41	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. <i>Blood</i> , 2018, 131, 2720-2729.	0.6	10
42	A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. <i>Nature Communications</i> , 2018, 9, 1107.	5.8	63
43	Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 97-110.	0.8	20
44	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. <i>Leukemia</i> , 2018, 32, 2706-2709.	3.3	2
45	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. <i>JAMA Oncology</i> , 2018, 4, e182453.	3.4	27
46	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1345-1348.	1.3	4
47	SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. <i>Cell Stem Cell</i> , 2018, 23, 355-369.e9.	5.2	68
48	Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. <i>PLoS ONE</i> , 2018, 13, e0195956.	1.1	4
49	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. <i>Cell Reports</i> , 2018, 23, 3127-3136.	2.9	68
50	Health Care and out-of-Pocket (OOP) Costs Among Medicare Beneficiaries Diagnosed with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2018, 132, 4730-4730.	0.6	1
51	Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2018, 132, 1552-1552.	0.6	3
52	Role of Enhanced Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment. <i>Blood</i> , 2018, 132, 1358-1358.	0.6	4
53	SIRT1 Mediates Enhanced Mitochondrial Oxidative Phosphorylation in Chronic Myelogenous Leukemia Stem Cells. <i>Blood</i> , 2018, 132, 932-932.	0.6	2
54	Standard Processing of Apheresis Products for HSCT Provides Significant Cost Savings over Automated Processing without Impact on Time or Product Quality. <i>Blood</i> , 2018, 132, 5693-5693.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	0.6	14
56	Association of Gene Expression Patterns in Bone Marrow Cells with Likelihood of Treatment Free Remission after TKI Discontinuation. <i>Blood</i> , 2018, 132, 1721-1721.	0.6	0
57	TNF- $\alpha$ -Induced Bone Marrow Stromal Progenitor Alterations Enhance Leukemic Stem Cell Growth and Treatment Resistance Via Increased CXCL1-CXCR2 Signaling. <i>Blood</i> , 2018, 132, 875-875.	0.6	1
58	CXCR4 Has a CXCL12-Independent Essential Role in MLL-AF9 Driven Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 774-774.	0.6	0
59	Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. <i>Blood</i> , 2017, 129, 1008-1020.	0.6	58
60	Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia. <i>Open Medicine (Poland)</i> , 2017, 12, 76-85.	0.6	7
61	Novel approaches to therapy in CML. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 115-120.	0.9	27
62	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 2392-2406.	3.9	64
63	Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes. <i>PLoS ONE</i> , 2017, 12, e0171473.	1.1	2
64	Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia. <i>Oncotarget</i> , 2017, 8, 10809-10821.	0.8	13
65	<i>Hoxa9</i> and <i>Hoxa10</i> induce CML myeloid blast crisis development through activation of <i>Myb</i> expression. <i>Oncotarget</i> , 2017, 8, 98853-98864.	0.8	4
66	Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 975-991.	3.9	44
67	In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0166891.	1.1	72
68	Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. <i>Blood</i> , 2016, 128, 2671-2682.	0.6	89
69	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	5.8	218
70	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. <i>Science Translational Medicine</i> , 2016, 8, 355ra117.	5.8	130
71	Deregulated hedgehog pathway signaling is inhibited by the smoothed antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. <i>Scientific Reports</i> , 2016, 6, 25476.	1.6	66
72	Role of CXCL12-Expressing Bone Marrow Populations in Leukemic Stem Cell Regulation. <i>Blood</i> , 2016, 128, 26-26.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	0.6	3
74	Long-Term Morbidity and Mortality Experienced By Chronic Myeloid Leukemia (CML) Patients after Allogeneic Hematopoietic Cell Transplantation (HCT) - a Report from BMTSS-2. <i>Blood</i> , 2016, 128, 823-823.	0.6	0
75	Enhanced Targeting of FLT3-ITD+AML Stem Cells through Combined Inhibition of SIRT1 and Autophagic Flux. <i>Blood</i> , 2016, 128, 31-31.	0.6	31
76	Progressive Decline in Late Mortality after Hematopoietic Cell Transplantation (HCT) over 40 Years - a Report from BMTSS. <i>Blood</i> , 2016, 128, 691-691.	0.6	2
77	BCL11B Is a Key Regulator of T-Lineage Differentiation during the Initial Stages of Human Thymopoiesis. <i>Blood</i> , 2016, 128, 2657-2657.	0.6	0
78	Leukemia-Induced Dysregulation of Bone Marrow Skeletal Stem Cells (SSC) Subpopulations and Their Hematopoietic Supportive Function. <i>Blood</i> , 2016, 128, 935-935.	0.6	0
79	Inhibition of CML Development Following Conditional SIRT1 Deletion in Transgenic BCR-ABL Mice. <i>Blood</i> , 2016, 128, 931-931.	0.6	0
80	MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. <i>Blood</i> , 2015, 125, 1302-1313.	0.6	133
81	Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development. <i>Blood</i> , 2015, 125, 2678-2688.	0.6	111
82	Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells. <i>Current Opinion in Hematology</i> , 2015, 22, 324-329.	1.2	42
83	Influence of Bone Marrow Microenvironment on Leukemic Stem Cells. <i>Advances in Cancer Research</i> , 2015, 127, 227-252.	1.9	37
84	Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10786-10791.	3.3	92
85	HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. <i>Cell Stem Cell</i> , 2015, 17, 597-610.	5.2	75
86	The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3737-3737.	0.6	3
87	Inhibition of CML Stem Cell Renewal By the Porcupine Inhibitor WNT974. <i>Blood</i> , 2015, 126, 54-54.	0.6	3
88	Granulocytes Affect Double-Strand Break Repair Assays in Primary Human Lymphocytes. <i>PLoS ONE</i> , 2014, 9, e93185.	1.1	2
89	ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance. <i>PLoS Genetics</i> , 2014, 10, e1004414.	1.5	31
90	SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells. <i>Cell Stem Cell</i> , 2014, 15, 431-446.	5.2	187

#	ARTICLE	IF	CITATIONS
91	Iron chelators induce autophagic cell death in multiple myeloma cells. <i>Leukemia Research</i> , 2014, 38, 988-996.	0.4	40
92	Leukemia cells make ruthless competitors. <i>Blood</i> , 2014, 124, 2900-2901.	0.6	0
93	Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. <i>Blood</i> , 2014, 123, 2826-2837.	0.6	87
94	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. <i>Blood</i> , 2014, 124, 1492-1501.	0.6	134
95	Inhibition of CML Stem Cell Growth By Targeting WNT Signaling Using a Porcupine Inhibitor. <i>Blood</i> , 2014, 124, 3130-3130.	0.6	4
96	Inhibition of HDAC8 Reactivates p53 and Abrogates Leukemia Stem Cell Activity in CBF $\hat{1}$ -SMMHC Associated Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 363-363.	0.6	8
97	Do Changes in Transplant Practice Influence Risk of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia after Autologous Hematopoietic Cell Transplantation (aHCT) for Non-Hodgkin Lymphoma (NHL)? <i>Blood</i> , 2014, 124, 430-430.	0.6	2
98	Cooperative Targeting of Bcl-2 Family Proteins By ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells. <i>Blood</i> , 2014, 124, 512-512.	0.6	5
99	The Role of Ribosomal Protein Deficiency in T-MDS Pathogenesis. <i>Blood</i> , 2014, 124, 3242-3242.	0.6	0
100	Cytopenias in the Early Post-Autologous Hematopoietic Cell Transplantation (aHCT) Period Predict for Subsequent Development of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia (t-MDS/AML) Among Patients with Lymphoma. <i>Blood</i> , 2014, 124, 2507-2507.	0.6	45
101	Acute Myeloid Leukemia-Derived Exosomes Transform Bone Marrow Niche into Leukemic Niche. <i>Blood</i> , 2014, 124, 352-352.	0.6	0
102	Increased p53 Acetylation By SIRT1 Inhibition Is Required for Optimal Activation of p53 Activity and Significantly Enhances the Ability of HDM2 Inhibitors to Target CML LSC. <i>Blood</i> , 2014, 124, 4521-4521.	0.6	1
103	Contribution of Leukemia-Induced Alterations in Mesenchymal Cell Subpopulations to Altered Regulation of Leukemic and Normal Stem Cells in the CML BM Microenvironment. <i>Blood</i> , 2014, 124, 4509-4509.	0.6	0
104	Role of Enhanced Microenvironmental Interleukin-1 (IL-1) Expression and Increased IL-1 Responsiveness in Persistence of Leukemia Stem Cells in TKI Treated CML Patients. <i>Blood</i> , 2014, 124, 4357-4357.	0.6	0
105	Effective and Selective Elimination of CML Stem Cells Using Novel Ethacrynic Acid Derivatives. <i>Blood</i> , 2014, 124, 4508-4508.	0.6	0
106	GADD45a Is a Tumor Suppressor in BCR-ABL-Driven Leukemogenesis. <i>Blood</i> , 2014, 124, 4530-4530.	0.6	0
107	Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. <i>Blood</i> , 2013, 121, 4175-4183.	0.6	105
108	Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt $\hat{1}$ -catenin signaling. <i>Blood</i> , 2013, 121, 1824-1838.	0.6	234



#	ARTICLE	IF	CITATIONS
109	The controversial role of Sirtuins in tumorigenesis – SIRT7 joins the debate. <i>Cell Research</i> , 2013, 23, 10-12.	5.7	19
110	Roles of SIRT1 in leukemogenesis. <i>Current Opinion in Hematology</i> , 2013, 20, 308-313.	1.2	28
111	Autocrine TNF- $\alpha$ production supports CML stem and progenitor cell survival and enhances their proliferation. <i>Blood</i> , 2013, 122, 3335-3339.	0.6	81
112	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4144-4157.	3.9	192
113	Leukemia-Derived Exosomes Reorganize Bone Marrow Microenvironment In AML. <i>Blood</i> , 2013, 122, 2455-2455.	0.6	1
114	Inhibition Of Microenvironmental Interleukin-1 Signaling Enhances TKI-Mediated Targeting Of Chronic Myelogenous Leukemia Stem Cells. <i>Blood</i> , 2013, 122, 512-512.	0.6	1
115	Heterogeneity Of Leukemic Stem Cell Capacity Of BCR-ABL+ Long-Term Hematopoietic Stem cells In CML Is Associated With Variability In MPL Expression. <i>Blood</i> , 2013, 122, 516-516.	0.6	0
116	Increased Risk Of Brain Tumors Among First-Degree Relatives Of Patients With Therapy-Related Myelodysplasia and Acute Myeloid Leukemia (t-MDS/AML). <i>Blood</i> , 2013, 122, 5228-5228.	0.6	0
117	Bone Marrow Osteoblast Ablation Enhances Short-Term Hematopoietic Stem Cells Without Altering Long-Term Hematopoietic Stem Cell Populations and Accelerates Leukemia Development. <i>Blood</i> , 2013, 122, 586-586.	0.6	0
118	Development Of t-MDS In Patients Undergoing Autologous Transplantation For Lymphoma Is Not Associated With Increased Frequency Of Mitochondrial DNA Mutations. <i>Blood</i> , 2013, 122, 1535-1535.	0.6	0
119	GADD45a Is a Tumor Suppressor In BCR-ABL-Driven Leukemogenesis. <i>Blood</i> , 2013, 122, 1467-1467.	0.6	0
120	MJ05, a Novel p53 Activating Compound, Effectively and Selectively Eliminates Human CML Stem/Progenitor Cells. <i>Blood</i> , 2013, 122, 1464-1464.	0.6	7
121	Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. <i>Blood</i> , 2012, 119, 6099-6108.	0.6	79
122	Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. <i>Blood</i> , 2012, 119, 1904-1914.	0.6	164
123	Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. <i>Carcinogenesis</i> , 2012, 33, 285-293.	1.3	23
124	Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. <i>Blood</i> , 2012, 119, 6187-6197.	0.6	42
125	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. <i>Blood</i> , 2012, 119, 1501-1510.	0.6	359
126	Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. <i>Cancer Cell</i> , 2012, 21, 266-281.	7.7	374



#	ARTICLE	IF	CITATIONS
127	Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia. <i>Cancer Cell</i> , 2012, 21, 577-592.	7.7	317
128	Selective Targeting of CML Progenitor/Stem Cells by the Class 1 Histone Deacetylase (HDAC) Inhibitor MS275 in Combination with Imatinib.. <i>Blood</i> , 2012, 120, 2791-2791.	0.6	0
129	Microenvironmental Protection of CML Stem and Progenitor Cells From Tyrosine Kinase Inhibitors Through N-Cadherin and Wnt Signaling. <i>Blood</i> , 2012, 120, 912-912.	0.6	1
130	Genomic Instability in CML-CP originates From the Most Primitive Imatinib-Refractory Leukemia Stem Cells. <i>Blood</i> , 2012, 120, 909-909.	0.6	0
131	Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. <i>Blood</i> , 2011, 118, 5565-5572.	0.6	220
132	A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells. <i>Blood</i> , 2011, 118, 1504-1515.	0.6	46
133	Leukemia-Induced Alterations in Bone Marrow Cytokine and Chemokine Levels Contribute to Altered Stem Cell Lodgment and Impairment of Normal Stem Cell Growth in CML. <i>Blood</i> , 2011, 118, 962-962.	0.6	0
134	Genetic Susceptibility to Therapy-Related Leukemia – Role of Expression Quantitative Trait Loci (eQTL). <i>Blood</i> , 2011, 118, 2438-2438.	0.6	0
135	Loss of Stress Sensor GADD45a Accelerates BCR-ABL-Driven Leukemogenesis. <i>Blood</i> , 2011, 118, 1668-1668.	0.6	1
136	Nrf2 Deficiency Leads to Altered Hematopoietic Stem Cell Function and Increased Sensitivity to Alkylating Agent Induced Myeloid Dysplasia,. <i>Blood</i> , 2011, 118, 3828-3828.	0.6	0
137	RNAi-Mediated Inhibition of Mcl-1 Expression Enhances Apoptosis in Imatinib-Treated CML Progenitors. <i>Blood</i> , 2011, 118, 1669-1669.	0.6	0
138	Role of MicroRNA-486-5p Overexpression In CML CD34+ Cells In Modulating BCR-ABL Mediated Hematopoietic Stem/Progenitor Cell Transformation and Imatinib Sensitivity. <i>Blood</i> , 2011, 118, 1667-1667.	0.6	0
139	Pharmacological Inhibition of the Stress-Related Deacetylase SIRT1 Enhances Eradication of CML stem Cells. <i>Blood</i> , 2011, 118, 448-448.	0.6	0
140	Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. <i>Blood</i> , 2010, 115, 2241-2250.	0.6	51
141	Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate. <i>Cancer Cell</i> , 2010, 17, 427-442.	7.7	245
142	BCR-ABL Gene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia. <i>Journal of Biological Chemistry</i> , 2010, 285, 5085-5096.	1.6	47
143	miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. <i>Cell</i> , 2010, 140, 652-665.	13.5	514
144	Altered Hematopoietic Cell Gene Expression Identifies Patients at Risk for Development of Therapy-Related Leukemia (t-MDS/AML). <i>Blood</i> , 2010, 116, 234-234.	0.6	1

#	ARTICLE	IF	CITATIONS
145	MicroRNA-486-5p Targets Foxo1 and Regulates Human Hematopoietic Stem Cell Proliferation and Erythroid Differentiation. <i>Blood</i> , 2010, 116, 3871-3871.	0.6	1
146	Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib. <i>Blood</i> , 2010, 116, 514-514.	0.6	8
147	Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients.. <i>Blood</i> , 2010, 116, 1220-1220.	0.6	4
148	Altered Niche Interactions of Leukemia Stem Cells In a Chronic Phase Chronic Myelogenous Leukemia (CML) Transgenic Mouse Model.. <i>Blood</i> , 2010, 116, 1212-1212.	0.6	0
149	An RNA Interference Screen Reveals a Critical Role for Mcl-1 In Survival of CML Progenitor Cells.. <i>Blood</i> , 2010, 116, 1203-1203.	0.6	0
150	Dose Dependent Effect of Deferasirox on Hematopoietic Progenitors of Myelodysplastic Syndrome. <i>Blood</i> , 2010, 116, 3994-3994.	0.6	0
151	SFK Inhibition with Dasatinib Results In Selective Targeting of Primitive Human Acute Myeloid Leukemia Stem and Progenitor Cells.. <i>Blood</i> , 2010, 116, 1053-1053.	0.6	0
152	SIRT1 Inhibition Induces Apoptosis In Human CML Progenitors by Enhancing p53 Acetylation and Activation. <i>Blood</i> , 2010, 116, 200-200.	0.6	0
153	CML-CP Mouse Model of Genomic Instability.. <i>Blood</i> , 2010, 116, 1210-1210.	0.6	0
154	Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. <i>Experimental Hematology</i> , 2009, 37, 206-214.	0.2	2
155	Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.. <i>Blood</i> , 2009, 114, 1428-1428.	0.6	15
156	A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR.. <i>Blood</i> , 2009, 114, 2194-2194.	0.6	4
157	Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. <i>Blood</i> , 2009, 114, 2771-2771.	0.6	2
158	FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(âˆ™) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.. <i>Blood</i> , 2009, 114, 3259-3259.	0.6	3
159	Gene Expression Changes in CD34+ Cells Precede Development of Therapy-Related Leukemia (t-MDS/AML) After Autologous Hematopoietic Cell Transplantation (aHCT) for Hodgkin (HL) or Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 677-677.	0.6	5
160	Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.. <i>Blood</i> , 2009, 114, 190-190.	0.6	0
161	Mechanisms of Susceptibility to 11q23 MLL Gene Locus Rearrangements in CD34+ Cells Exposed to Etoposide.. <i>Blood</i> , 2009, 114, 185-185.	0.6	0
162	Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.. <i>Blood</i> , 2009, 114, 855-855.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Characterization of Leukemia-Initiating Cells in a Transgenic Model of Chronic Phase Chronic Myelogenous Leukemia (CML).. Blood, 2009, 114, 858-858.	0.6	1
164	Role of the SIRT1 Deacetylase in Survival and Imatinib Resistance of CML CD34+ Progenitors.. Blood, 2009, 114, 189-189.	0.6	0
165	Genetic Susceptibility to Therapy-Related Leukemia (t-MDS/AML) After Hodgkin Lymphoma (HL) or Non-Hodgkin Lymphoma (NHL).. Blood, 2009, 114, 199-199.	0.6	0
166	Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research, 2008, 68, 9624-9633.	0.4	82
167	Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood, 2008, 111, 2329-2338.	0.6	96
168	Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38 <sup>+</sup> Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL <sup>-</sup> independent Signals. Blood, 2008, 112, 189-189.	0.6	10
169	Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years. Blood, 2008, 112, 194-194.	0.6	4
170	Growth of p210Bcr-Abl Transformed Human Hematopoietic Stem Cells in Immunodeficient Mice.. Blood, 2008, 112, 1072-1072.	0.6	0
171	Longitudinal Trends in Peripheral Blood Parameters Predict Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/ AML) after Autologous Transplantation for Lymphoma.. Blood, 2008, 112, 2133-2133.	0.6	0
172	BCR-Tyrosine 177 Plays an Essential Role in Ras and Akt Activation and in Human Hematopoietic Progenitor Transformation in Chronic Myelogenous Leukemia. Cancer Research, 2007, 67, 7045-7053.	0.4	59
173	Growth Factor Stimulation Reduces Residual Quiescent Chronic Myelogenous Leukemia Progenitors Remaining after Imatinib Treatment. Cancer Research, 2007, 67, 1113-1120.	0.4	78
174	Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood, 2007, 109, 5411-5421.	0.6	54
175	Effective Induction of Apoptosis in Chronic Myeloid Leukemia CD34+ Cells by the Histone Deacetylase Inhibitor LAQ824 in Combination with Imatinib.. Blood, 2007, 110, 1031-1031.	0.6	8
176	The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.. Blood, 2007, 110, 1082-1082.	0.6	2
177	Normal Short-Term but Reduced Long-Term Engraftment Capacity of CML Hematopoietic Cells with Skewed Myeloid Lineage Differentiation Is Seen in an Improved Mouse Model of Human Hematopoiesis.. Blood, 2007, 110, 3383-3383.	0.6	1
178	Enhanced Phosphorylation and Altered Localization Lead to Impairment of p27kip Activity in CML Progenitor Cells Despite Enhanced Protein Translation and Expression.. Blood, 2007, 110, 999-999.	0.6	3
179	A Novel Assay for Development of Chromosomal Lesions in Human CD34+ Cells Following Exposure to Ionizing Radiation Reveals Increased Susceptibility To Acquire Unstable Chromosomal Lesions in CML CD34+ Cells.. Blood, 2007, 110, 997-997.	0.6	0
180	Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment.. Blood, 2007, 110, 3378-3378.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Small Molecules Targeting Rad51 Recombinase Synergize with Imatinib and Overcome Imatinib-Resistance in CML.. Blood, 2007, 110, 466-466.	0.6	0
182	Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.. Blood, 2007, 110, 2944-2944.	0.6	0
183	Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP).. Blood, 2007, 110, 1038-1038.	0.6	0
184	Effect of Inhibition of Grb2 Expression on BCR-ABL Mediated Transformation of Primary Human Hematopoietic Cells.. Blood, 2007, 110, 1020-1020.	0.6	0
185	Escaping inhibition by self-mutation. Blood, 2006, 108, 7-7.	0.6	1
186	Nilotinib Inhibits Bcr-Abl Kinase Activity in CML Progenitor Cells More Effectively Than Imatinib but Is Equipotent in Inducing Growth Inhibition.. Blood, 2006, 108, 744-744.	0.6	1
187	Rapid Telomere Loss in Hematopoietic Cells Associated with Development of t-MDS after Autologous Transplantation for Lymphoma.. Blood, 2006, 108, 2644-2644.	0.6	0
188	Altered Gene Expression in CD34+ Cells from PBSC Grafts from Patients Developing t-MDS Following Autologous Transplantation for Lymphoma.. Blood, 2006, 108, 2326-2326.	0.6	0
189	Role of BCR/ABL Gene Expression Levels in Determining the Phenotype and Imatinib Sensitivity of Transformed Human Hematopoietic Cells.. Blood, 2006, 108, 2122-2122.	0.6	0
190	Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood, 2005, 105, 2093-2098.	0.6	197
191	Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2005, 23, 6699-6711.	0.8	45
192	Enhanced Engraftment and Maintenance of CXCR4 Expressing CD34+ Cells In Vivo Is Related to Microenvironmental Interactions, Rather Than Direct Receptor Signaling to Hematopoietic Stem Cells.. Blood, 2005, 106, 2306-2306.	0.6	2
193	Pre-Stimulation of CML CD34+ Cells with High Concentrations of Growth Factors Counters Imatinib-Mediated Proliferation Suppression and Enhances Apoptosis of Non-Dividing Cells.. Blood, 2005, 106, 2479-2479.	0.6	0
194	Effects of Elevated BCR/ABL Expression Level on Cellular Transformation and Sensitivity to Imatinib in Primitive Human Hematopoietic Cells.. Blood, 2005, 106, 1998-1998.	0.6	0
195	BCR/ABL Tyrosine 177 Complexes with Grb2, Gab2 and Shp2, and Plays a Critical Role in Akt Activation and Altered p27 Signaling in BCR/ABL Transformed Human CD34+ Cells.. Blood, 2005, 106, 1988-1988.	0.6	6
196	The MDS-Associated Gene DLK Modulates Gene Expression in Human Myeloid Cells by Altering the Activity of Multiple Transcription Factors.. Blood, 2005, 106, 3428-3428.	0.6	0
197	Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors. Cancer Research, 2004, 64, 5322-5331.	0.4	71
198	Autologous hematopoietic cell transplantation for chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 715-732.	0.9	11

#	ARTICLE	IF	CITATIONS
199	BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. <i>Blood</i> , 2004, 103, 3167-3174.	0.6	153
200	Overcoming imatinib resistance. <i>Blood</i> , 2004, 103, 4-5.	0.6	6
201	Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. <i>Blood</i> , 2004, 104, 1898-1906.	0.6	139
202	Expression of DLK/PREF1 Results in Inhibition of Human Myeloid Cell Differentiation and Proliferation through Distinct Molecular Mechanisms.. <i>Blood</i> , 2004, 104, 202-202.	0.6	6
203	Effect of Growth Factor Stimulation on Imatinib-Mediated Proliferation Inhibition and Apoptosis of CML CD34+ Cells.. <i>Blood</i> , 2004, 104, 2967-2967.	0.6	13
204	Feasibility and Efficacy of Mobilization of BCR/ABL- PBSC in CML Patients Receiving Imatinib.. <i>Blood</i> , 2004, 104, 2858-2858.	0.6	1
205	Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. <i>Blood</i> , 2003, 101, 4701-4707.	0.6	501
206	Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. <i>Blood</i> , 2002, 99, 3792-3800.	0.6	240
207	Contact with fibronectin enhances preservation of normal but not chronic myelogenous leukemia primitive hematopoietic progenitors. <i>Experimental Hematology</i> , 2002, 30, 324-332.	0.2	22
208	Solid Cancers After Bone Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2001, 19, 464-471.	0.8	300
209	Abnormal growth factor modulation of $\alpha$ 21-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors. <i>British Journal of Haematology</i> , 2001, 115, 845-853.	1.2	13
210	Growth factor stimulation enhances integrin-mediated migration but not adhesion of cml progenitors. <i>Experimental Hematology</i> , 2000, 28, 56.	0.2	0
211	Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. <i>Blood</i> , 2000, 95, 1588-1593.	0.6	270
212	The Effect of Interferon- $\gamma$ on Beta-1 Integrin Mediated Adhesion and Growth Regulation in Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1998, 28, 241-254.	0.6	42
213	Inhibition of BCR-ABL Expression With Antisense Oligodeoxynucleotides Restores $\alpha$ 21 Integrin-Mediated Adhesion and Proliferation Inhibition in Chronic Myelogenous Leukemia Hematopoietic Progenitors. <i>Blood</i> , 1998, 91, 3414-3422.	0.6	66
214	Inhibition of BCR-ABL Expression With Antisense Oligodeoxynucleotides Restores $\alpha$ 21 Integrin-Mediated Adhesion and Proliferation Inhibition in Chronic Myelogenous Leukemia Hematopoietic Progenitors. <i>Blood</i> , 1998, 91, 3414-3422.	0.6	17
215	Integrin-Mediated Regulation of Hematopoiesis: Do BCR/ABL-Induced Defects in Integrin Function Underlie the Abnormal Circulation and Proliferation of CML Progenitors?. <i>Acta Haematologica</i> , 1997, 97, 40-52.	0.7	83
216	Autologous Transplantation Therapy for Chronic Myelogenous Leukemia. <i>Blood</i> , 1997, 89, 2623-2634.	0.6	48

#	ARTICLE	IF	CITATIONS
217	Secondary Malignancies After Hematopoietic Cell Transplantation. , 0, , 962-977.		3
218	Secondary Malignancies after Hematopoietic Cell Transplantation. , 0, , 1638-1652.		0
219	Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study. Journal of Clinical Oncology, 0, , .	0.8	7